Though early parenteral iron supplementations with erythropoietin (EPO) were found to be beneficial for the management of anaemia, especially in end-stage renal disease patients, it is not widely practiced as it is not feasible and affordable in India [25]. Here, EPO is linked to stage 5 chronic kidney disease.